# A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations

> **NCT05420779** · PHASE2 · RECRUITING · sponsor: **Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.** · enrollment: 125 (estimated)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** TSL-1502 capsules(low dose)
- **DRUG:** TSL-1502 capsules(high dose)
- **DRUG:** Investigator's choice of chemotherapy

## Key facts

- **NCT ID:** NCT05420779
- **Lead sponsor:** Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-30
- **Primary completion:** 2024-12-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05420779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05420779, "A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05420779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*